AK-US-001-0105
Brief description of study
The primary objective of this study is to evaluate the effect of EFX compared to placebo on achieving NASH resolution AND fibrosis regression in subjects with fibrosis stage 2 or 3 at Week 52. Subjects meeting the study's eligibility criteria will randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
